Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Technology Insight: transcoronary ablation of septal hypertrophy

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 101–107 (2005)Cite this article

Abstract

Outflow tract obstruction affects 5-10% of hypertrophic cardiomyopathy patients. Although myectomy is the gold standard treatment, alcohol septal ablation has emerged as an alternative nonsurgical procedure. Burri and Sigwart present a round up of the past 10 years' experience and discuss the pros and cons of this procedure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Angiography of the left coronary artery
Figure 3: Echocardiography before and after injection of alcohol into target septal vessel

Similar content being viewed by others

References

  1. Maron BJ et al. (2000) Epidemiology of Hypertrophic Cardiomyopathy-Related Death: Revisited in a Large Non-Referral-Based Patient Population. Circulation 102: 858–864

    Article  CAS  Google Scholar 

  2. Maron MS et al. (2003) Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. N Engl J Med 348: 295–303

    Article  Google Scholar 

  3. Maron BJ et al. (1987) Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 316: 780–789

    Article  CAS  Google Scholar 

  4. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287: 1308–1320.

    PubMed  Google Scholar 

  5. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346: 211–214

    Article  CAS  Google Scholar 

  6. Brugada P et al. (1989) Transcoronary chemical ablation of ventricular tachycardia. Circulation 79: 475–482

    Article  CAS  Google Scholar 

  7. Kuhn H et al. (1997) Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 18: 846–851

    Article  CAS  Google Scholar 

  8. Spencer WH III and Roberts R (2000) Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: The Need for a Registry. Circulation 102: 600–601

    Article  Google Scholar 

  9. Gietzen FH et al. (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 106: 454–459

    Article  Google Scholar 

  10. Kuhn H et al. (1999) Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J 20: 1808–1817

    Article  CAS  Google Scholar 

  11. Lakkis NM et al. (1998) Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98: 1750–1755

    Article  CAS  Google Scholar 

  12. Nagueh SF et al. (1998) Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 32: 225–229

    Article  CAS  Google Scholar 

  13. Runquist LH et al. (2002) Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 90: 1020–1022

    Article  Google Scholar 

  14. Flores-Ramirez R et al. (2001) Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 37: 208–214

    Article  CAS  Google Scholar 

  15. Henein MY et al. (1999) Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 34: 1117–1122

    Article  CAS  Google Scholar 

  16. Park T-H et al. (2002) Acute Effect of Nonsurgical Septal Reduction Therapy on Regional Left Ventricular Asynchrony in Patients With Hypertrophic Obstructive Cardiomyopathy. Circulation 106: 412–415

    Article  Google Scholar 

  17. Nagueh SF et al. (1999) Changes in Left Ventricular Diastolic Function 6 Months After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy. Circulation 99: 344–347

    Article  CAS  Google Scholar 

  18. Nagueh SF et al. (1999) Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 34: 1123–1128

    Article  CAS  Google Scholar 

  19. Sitges M et al. (2003) Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 91: 817–821

    Article  Google Scholar 

  20. Boekstegers P et al. (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38: 846–853

    Article  CAS  Google Scholar 

  21. Nagueh SF et al. (2001) Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 103: 1844–1850

    Article  CAS  Google Scholar 

  22. Mazur W et al. (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103: 1492–1496

    Article  CAS  Google Scholar 

  23. Lakkis NM et al. (2000) Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 36: 852–855

    Article  CAS  Google Scholar 

  24. Faber L et al. (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98: 2415–2421

    Article  CAS  Google Scholar 

  25. Faber L et al. (1999) Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv 47: 462–466

    Article  CAS  Google Scholar 

  26. Okayama H et al. (2001) Usefulness of selective myocardial contrast echocardiography in percutaneous transluminal septal myocardial ablation: a case report. Jpn Circ J 65: 842–844

    Article  CAS  Google Scholar 

  27. Faber L et al. (2000) Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr 13: 1074–1079

    Article  CAS  Google Scholar 

  28. Harada T et al. (2002) Papillary muscles identified by myocardial contrast echocardiography in preparation for percutaneous transluminal septal myocardial ablation. Acta Cardiol 57: 25–27

    Article  Google Scholar 

  29. Faber L et al. (2000) Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 83: 326–331

    Article  CAS  Google Scholar 

  30. Seggewiss H et al. (2000) Improvement of acute results after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy during mid-term follow-up [abstract]. J Am Coll Cardiol 35: 188A

    Article  Google Scholar 

  31. Firoozi S et al. (2002) Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 23: 1617–1624

    Article  CAS  Google Scholar 

  32. Nagueh SF et al. (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38: 1701–1706

    Article  CAS  Google Scholar 

  33. Qin JX et al. (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38: 1994–2000

    Article  CAS  Google Scholar 

  34. Gietzen FH et al. (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20: 1342–1354

    Article  CAS  Google Scholar 

  35. Seggewiss H et al. (2000) Age related acute results of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 35: 188A

    Article  Google Scholar 

  36. Oomman A et al. (2001) Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results. J Invasive Cardiol 13: 526–530

    CAS  PubMed  Google Scholar 

  37. Welge D et al. (2002) Long-term outcome after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 39: 173A

    Article  Google Scholar 

  38. Kim JJ et al. (1999) Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 83: 1220–1223

    Article  CAS  Google Scholar 

  39. Knight C et al. (1997) Nonsurgical Septal Reduction for Hypertrophic Obstructive Cardiomyopathy : Outcome in the First Series of Patients. Circulation 95: 2075–2081

    Article  CAS  Google Scholar 

  40. Kuhn H et al. (2004) Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. Z Kardiol 93: 23–31

    Article  CAS  Google Scholar 

  41. Dimitrow PP et al. (2001) The risk of alcohol leakage into the left anterior descending coronary artery during non-surgical myocardial reduction in patients with obstructive hypertrophic cardiomyopathy. Eur Heart J 22: 437–438

    Article  CAS  Google Scholar 

  42. Kern MJ et al. (2002) Delayed occurrence of complete heart block without warning after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv 56: 503–507

    Article  Google Scholar 

  43. Chang SM et al. (2003) Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 42: 296–300

    Article  Google Scholar 

  44. ten Berg JM et al. (1994) Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation 90: 1781–1785

    Article  CAS  Google Scholar 

  45. Kazmierczak J et al. (1998) Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 80: 257–262

    Article  CAS  Google Scholar 

  46. Valettas N et al. (2003) Alcohol septal ablation complicated by complete heart block and permanent pacemaker failure. Catheter Cardiovasc Interv 58: 189–193

    Article  Google Scholar 

  47. Braunwald E et al. (2002) Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy. Circulation 106: 1312–1316

    Article  Google Scholar 

  48. Maron BJ et al. (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42: 1687–1713

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital, Geneva

    Haran Burri & Ulrich Sigwart

  2. Cardiology, University of Geneva, Switzerland

    Haran Burri & Ulrich Sigwart

Authors
  1. Haran Burri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Sigwart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Sigwart.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burri, H., Sigwart, U. Technology Insight: transcoronary ablation of septal hypertrophy. Nat Rev Cardiol 2, 101–107 (2005). https://doi.org/10.1038/ncpcardio0095

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0095

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing